Planejamento, síntese e avaliação farmacológica de novos candidatos a protótipos de fármacos anti-inflamatórios

• Ano de defesa: 2009
• Autor(a) principal: GOMES, Marcelo do Nascimento
• Orientador(a): MENEGATTI, Ricardo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Goiás
• Programa de Pós-Graduação: Mestrado em Ciências Farmacêuticas
• Departamento: Ciências da Saúde - Farmácia
• País: BR
• Palavras-chave em Português: Química medicinal; modelagem molecular; inflamação; anti-inflamatórios; derivados pirazólicos; 1.Química medicinal 2.Modelagem molecular 3.Inflamação 4.Anti-inflamatórios 5.Derivados pirazólicos
• Palavras-chave em Inglês: Medicinal chemistry; molecular modeling; inflammation; anti-inflammatory; pyrazolics derivate
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE::FARMACIA
• Link de acesso: http://repositorio.bc.ufg.br/tede/handle/tde/2136

In the field of a research line that seeks the planning, the synthesis and the pharmacologycal evaluation of new candidates to prototypes of anti-inflammatory drugs, we will describe in this project the planning of derived new pyrazolics (LQFM 002-003), originally drawn starting from the nerolidilcatecol (24) and arylsulfonilpiperazines, (25) that present profile inhibition of the enzyme sPLA2. The compounds (E)-N-(3,7-dimethylocta-2,6-dienyl)-1,3-dimethtyl-1-H-pyrazol-5-amine (LQFM 002) and (E)-N-(3,7-dimethylocta-2,6-dienyl)-1,3-dimethyl-4-((4-methylpiperazin-1-il) methyl)-1H-pyrazol-5-amine (LQFM 003), were submitted to pharmacologycal rehearsals in vitro, seeking to evaluate the enzymatic inhibition activity of the sPLA2. For the prototype (LQFM 002) the inhibition halos were 14,43 ± 6,28%, 16,68 ± 2,45%, 23,61 ± 2,62%, 37,06 ± 3,25%, in the doses of 250, 500, 1000 and 2000 μg/mL respectively. For the compound (LQFM 003), the halos were 1,85 ± 1,38%, 9,29 ± 3,33%, 7,82 ± 3,32%, 13,21 ± 3,22%, respectively. Subsequently the rehearsal in vivo was accomplished to evaluate the profile of cellular migration. Being also analyzed the concentration of plasmatic protein by the methodology of the Evans of blue once the inflammatory process was induced. The compound (LQFM 002) presented inhibition on cellular migration of 50,46 ± 14,34% in the peritonit test, 68,7 ± 2,65% in the pleurisy test and reduction of 40,1 ± 6,40% of the plasmatics proteins for the method of coloration of the Evans of blue. The compound (LQFM 003) presented 25,89 ± 5,39% inhibition, in the doses of 50 mg/Kg, characterizing, significant anti-inflammatory profile for the prototype (LQFM 002). Parallel to the pharmacologycal synthetic work and, we carried out theoretical studies through the application of molecular dynamics. The parameters of the enzyme sPLA2 was more effective through the applications of the water box's, once the smaller state energy observed was of -175000kcal/mol. At the end of this project, we can conclude that the structural planning applied in the project was validated through the applications of the pharmacologycal rehearsals, once both molecules were recognized by the enzyme sPLA2 and they presented anti-inflammatory activity in the rehearsal of cellular migration. In addition, the applied synthetic methodology for obtaining of the prototypes pyrazolics (LQFM 002-003) studied was satisfatory.